Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, if he will request that the National Institute for Health and Care Excellence examines the use of Sativex or other appropriate cannabis derivatives for treatment of spasticity due to stroke.

Sativex (nabiximols) does not have a marketing authorisation for use in the treatment of spasticity due to stroke and there are no current plans to ask the National Institute for Health and Care Excellence to issue guidance on the drug or other cannabis derivatives for this indication.